Conformational Blockade of RAS in Cancer

Complex-Directed Therapies to Actively Prevent Resistance

RAS has the highest frequency of mutation of any oncogene in human cancer. Quanta Therapeutics is pioneering allosteric modulation to directly restore conformational control of active RAS signaling at the cell membrane to inhibit the full scope of RAS-driven cancer types. Our team applies deep biologic insight, unique protein conformation detection technology and sophisticated medicinal chemistry expertise to develop novel small molecules as first-in-class precision medicines breaking the resistance paradigms of targeted therapy in oncology.

Leadership

Management Team

Perry Nisen, MD PhD
Chief Executive Officer

Cameron Pitt, PhD
Chief Business Officer

Hong Lin, PhD
SVP of Drug Discovery

Juan Luengo, PhD
SVP of Chemistry

Neil Johnson, PhD
Sr Dir. of Medicinal Chemistry

Elizabeth Donohue Vo, PhD
Sr Dir. of Biology


Board of Directors

Samuel Saks, MD
Chairperson

Perry Nisen, MD PhD
CEO, Director

Cameron Pitt, PhD
CBO, Director

Maha Katabi, PhD
Director

Arjun Goyal, MD
Director

Maria Fardis, PhD MBA
Director


Scientific Advisory Board

Frank McCormick, PhD FRS
UCSF

Andrej Sali, PhD
UCSF

Ben Cravatt, PhD
Scripps

Phil Baran, PhD
Scripps


Investors

sofinnova investments logo

vida ventures logo

surveyor logo

longitude capital logo

BVF partners logo

logos capital logo

abbvie logo

Our Pipeline

Quanta’s allosteric approach makes oncogenic RAS(ON) conventionally druggable.

 

Career Opportunities

We are seeking highly motivated drug-hunters to join our passionate and experienced scientific team.


Senior Associate Scientist


R&D Project Manager